|
|
Michael Doherty is a highly experienced executive in both the pharmaceutical and diagnostics industries, at the forefront of precision medicine. He has a deep knowledge of regulatory affairs and product development and recently achieved ground-breaking approval of the first comprehensive NGS panel for Foundation Medicine (F1CDx) which combines genomic analyses with companion diagnostics.
Driven by innovation, Doherty was given the responsibility inside Roche and Genentech to build and lead an Innovation Function in Product Development with the task of disrupting the drug development process.
He also led Roche's Global Regulatory Affairs function through the critical growth years, where Roche was able to launch the number one oncology portfolio with a franchise of monoclonal antibodies and targeted medicines. Doherty was a member of the Roche portfolio committee from 2002 to 2016.
He received his BSc in Physiology and Biochemistry with a subsidiary in Chemistry from the University of Reading, U.K., a Fellowship of the Institute of Medical Laboratory Science from Manchester Metropolitan University, U.K., and a Diploma in Management Studies from the University of Portsmouth, U.K.
Driven by innovation, Doherty was given the responsibility inside Roche and Genentech to build and lead an Innovation Function in Product Development with the task of disrupting the drug development process.
He also led Roche's Global Regulatory Affairs function through the critical growth years, where Roche was able to launch the number one oncology portfolio with a franchise of monoclonal antibodies and targeted medicines. Doherty was a member of the Roche portfolio committee from 2002 to 2016.
He received his BSc in Physiology and Biochemistry with a subsidiary in Chemistry from the University of Reading, U.K., a Fellowship of the Institute of Medical Laboratory Science from Manchester Metropolitan University, U.K., and a Diploma in Management Studies from the University of Portsmouth, U.K.
